Clinical trial
Use of Alfuzosin in Stone Treatment With ESWL
NCT00388271 · Singapore General Hospital, Other · Withdrawn
Key facts
| NCT number | NCT00388271 |
|---|---|
| Title | Use of Alfuzosin in Stone Treatment With ESWL |
| Official title | To Investigate if Alpha-blocker Therapy (Alfuzosin) Increases Stone Free Rates and Improves Pain Control After ESWL (Extra-corporeal Shock Wave Lithotripsy) for Renal and Ureteric Stones. |
| Lead sponsor | Singapore General Hospital, Other |
| Collaborators | Sanofi Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Urinary Calculi |
| Intervention type | Drug |
| Interventions | Alfuzosin (Xatral), standard treatment |
| Enrollment | 0 |
| Start date | Oct 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Oct 16, 2006 |
| Last update posted | Feb 10, 2017 |
| Countries | Singapore |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: